AMAG Pharmaceuticals (NASDAQ:AMAG) received a $18.00 price target from investment analysts at Cantor Fitzgerald in a report issued on Wednesday. The firm presently has a “hold” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential downside of 10.67% from the stock’s current price.
AMAG has been the subject of several other reports. Deutsche Bank set a $23.00 target price on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, September 20th. B. Riley boosted their target price on AMAG Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, August 6th. Jefferies Financial Group restated a “hold” rating and set a $22.00 target price on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. Finally, ValuEngine lowered AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 14th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $22.87.
Shares of NASDAQ:AMAG opened at $20.15 on Wednesday. The stock has a market cap of $739.44 million, a price-to-earnings ratio of -3.64 and a beta of 0.48. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $26.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.06 and a quick ratio of 1.95.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.54). The firm had revenue of $146.25 million for the quarter, compared to the consensus estimate of $156.26 million. AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) earnings per share. sell-side analysts expect that AMAG Pharmaceuticals will post -3.43 EPS for the current year.
In other news, CEO William K. Heiden sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the transaction, the chief executive officer now directly owns 328,015 shares in the company, valued at approximately $8,200,375. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.00% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Advisors Asset Management Inc. grew its position in shares of AMAG Pharmaceuticals by 791.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 52,356 shares during the period. Opaleye Management Inc. acquired a new position in shares of AMAG Pharmaceuticals in the 2nd quarter valued at approximately $8,190,000. Macquarie Group Ltd. grew its position in shares of AMAG Pharmaceuticals by 3,646.1% in the 2nd quarter. Macquarie Group Ltd. now owns 516,956 shares of the specialty pharmaceutical company’s stock valued at $10,081,000 after purchasing an additional 503,156 shares during the period. Renaissance Technologies LLC grew its position in shares of AMAG Pharmaceuticals by 6.2% in the 2nd quarter. Renaissance Technologies LLC now owns 1,641,100 shares of the specialty pharmaceutical company’s stock valued at $32,001,000 after purchasing an additional 96,300 shares during the period. Finally, Employees Retirement System of Texas grew its position in shares of AMAG Pharmaceuticals by 13.6% in the 2nd quarter. Employees Retirement System of Texas now owns 75,000 shares of the specialty pharmaceutical company’s stock valued at $1,463,000 after purchasing an additional 9,000 shares during the period.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: What are the Benefits of Index Funds?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.